Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Aminosalicylates have been designed to target specific gastrointestinal tract segments, ensuring effective delivery and absorption. Azo compounds such as sulfasalazine, balsalazide, and olsalazine contain 5-ASA bound by an azo bond to an inert compound or another 5-ASA molecule, allowing targeted drug delivery. At the same time, mesalamine is a unique formulation that packages 5-ASA itself in various ways to deliver it to different segments of the small or large bowel.

Clinically, aminosalicylates show efficacy in inducing and maintaining remission in ulcerative colitis. They also treat mild to moderate Crohn's disease involving the colon or distal ileum. Their potential adverse effects include hypersensitivity reactions, gastrointestinal disturbances, renal tubular damage, interstitial nephritis, and worsening of colitis. Sulfasalazine, a type of aminosalicylate, has additional side effects, including headache, skin reactions, leukopenia, and a reversible decrease in sperm count.

Del capítulo 23:

article

Now Playing

23.4 : Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Chronic Bowel Disorders

65 Vistas

article

23.1 : Trastornos Intestinales Crónicos: Introducción

Drugs for Chronic Bowel Disorders

154 Vistas

article

23.2 : Medicamentos para el tratamiento del síndrome del intestino irritable con predominio diarreico

Drugs for Chronic Bowel Disorders

70 Vistas

article

23.3 : Medicamentos para el tratamiento del síndrome del intestino irritable con predominio de estreñimiento

Drugs for Chronic Bowel Disorders

67 Vistas

article

23.5 : Fármacos para el tratamiento de la enfermedad de Crohn en la EII con agentes inmunomoduladores

Drugs for Chronic Bowel Disorders

42 Vistas

article

23.6 : Fármacos para el tratamiento de la enfermedad de Crohn en la EII con agentes biológicos: anti-TNF

Drugs for Chronic Bowel Disorders

59 Vistas

article

23.7 : Fármacos para el tratamiento de la enfermedad de Crohn en la EII con glucocorticoides

Drugs for Chronic Bowel Disorders

40 Vistas

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados